SAN DIEGO, July 16, 2026 /PRNewswire/ — Inhibrx Biosciences, Inc. (“Inhibrx” or the “Company”) (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the “Second…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
